$MAZE News

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target

Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage

Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50

Wedbush Reiterates Outperform on Maze Therapeutics, Maintains $48 Price Target

BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics Announces Appointments to Its Board of Directors

BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk